Surgical treatment of locally far-advanced lung carcinoma

J Surg Oncol. 1981;17(3):283-6. doi: 10.1002/jso.2930170311.


It has been our policy to employ radical lung resection as a primary treatment whenever possible in locally far-advanced lung cancer. In order to assess the therapeutic results, a total of 132 patients with locally far-advanced lung cancer who had radical lung resection were reviewed. Postoperative mortality was 10%. A significant difference in survival was seen between those patients receiving no adjuvant therapy, radiation or single agent chemotherapy and those receiving cis-platinum-based polychemotherapy and/or immunotherapy (respective median survivals 14.25 and 25.68 months, P less than 0.05 Breslow test or failure rats). Aggressive surgery followed by effective adjuvant therapy in locally far-advanced Stage III lung carcinoma appears to produce acceptable survival results.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / surgery*
  • Adenocarcinoma / therapy
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / surgery*
  • Carcinoma, Squamous Cell / therapy
  • Humans
  • Immunotherapy
  • Lung Neoplasms / mortality
  • Lung Neoplasms / surgery*
  • Lung Neoplasms / therapy
  • Time Factors